MedTrace Logo

Combination Therapy (Provigil + Avonex) to Treat Cognitive Problems in MS

NCT00210301 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2006-09-07

No results posted yet for this study

Summary

MS has been associated with fatigue, attention problems, and a number of cognitive difficulties. There is no treatment approved yet to treat these problems. We hypothesize that the addition of Provigil to an existing immunomodulatory agent (Avonex) will lead to improved fatigue, attention, and overall cognition in MS patients with attention problems.

Conditions

  • Relapsing-Remitting Multiple Sclerosis

Interventions

DRUG

Provigil (modafinil)

Sponsors & Collaborators

  • Institute for Clinical Research

    lead OTHER

Principal Investigators

  • Jeffrey A Wilken, Ph.D. · Institute for Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00210301 on ClinicalTrials.gov